ALDX - Aldeyra Therapeutics, Inc.

QQQ $ 440.14 $ 0.64 (0.15 %)

DIA $ 388.61 $ -0.60 (-0.15 %)

SPY $ 517.03 $ -0.53 (-0.1 %)

TLT $ 90.74 $ -0.09 (-0.1 %)

GLD $ 214.14 $ -0.40 (-0.19 %)

Previous Close

$ 4.12

Open

$ 4.15

Bid

$ 4.08 x 200

Ask

$ 4.09 x 100

Day's Range

$ 4.04 - $ 4.16

52 Week Range

$ 1.42 - $ 11.97

Volume

305,616

Average Volume

Market Cap

244.79M

Beta (5Y Monthly)

$ 1.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	03-07-2024	12-31-2023	10-K
3	11-03-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-09-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-05-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	03-17-2022	12-31-2021	10-K
11	10-28-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	03-11-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-06-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-12-2020	12-31-2019	10-K
19	11-07-2019	09-30-2019	10-Q
20	08-09-2019	06-30-2019	10-Q
21	05-10-2019	03-31-2019	10-Q
22	03-08-2019	12-31-2018	10-K
23	11-14-2018	09-30-2018	10-Q
24	08-09-2018	06-30-2018	10-Q
25	05-15-2018	03-31-2018	10-Q
26	03-29-2018	12-31-2017	10-K
27	11-09-2017	09-30-2017	10-Q
28	08-07-2017	06-30-2017	10-Q
29	05-15-2017	03-31-2017	10-Q
30	03-30-2017	12-31-2016	10-K
31	11-14-2016	09-30-2016	10-Q
32	08-10-2016	06-30-2016	10-Q
33	05-09-2016	03-31-2016	10-Q
34	03-30-2016	12-31-2015	10-K
35	11-13-2015	09-30-2015	10-Q
36	08-14-2015	06-30-2015	10-Q
37	05-14-2015	03-31-2015	10-Q
38	03-23-2015	12-31-2014	10-K
39	11-12-2014	09-30-2014	10-Q
40	08-07-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Oppenheimer Reiterates Outperform on Aldey...
05/06/2024 11:46:39

Oppenheimer analyst Francois Brisebois reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Outperform and maintains $10 pri...

HC Wainwright & Co. Reiterates Buy on Alde...
05/06/2024 10:38:45

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

Aldeyra Therapeutics Highlights Recent Pre...
04/25/2024 11:26:39

aldeyra-therapeutics-and-2-other-stocks-under-5-insiders-are-buying

Aldeyra Therapeutics And 2 Other Stocks Un...
04/04/2024 10:23:06

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confide...

Oppenheimer Upgrades Aldeyra Therapeutics ...
04/03/2024 13:58:41

Oppenheimer analyst Francois Brisebois upgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Perform to Outperform and announces ...

HC Wainwright & Co. Reinstates Buy on Alde...
04/02/2024 12:43:21

HC Wainwright & Co. analyst Matthew Caufield reinstates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and announces $10 ...

Aldeyra Therapeutics Disclosed Clinical De...
03/28/2024 11:14:49

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 21:31:07

Aldeyra Therapeutics Reports Advancement O...
01/04/2024 12:06:05

Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, ...

On December 21, 2023, Aldeyra Therapeutics...
12/21/2023 21:19:12

As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to Aldeyra at any tim...

positive-news-for-skin-health-aldeyra-therapeutics-adx-629-achieves-key-milestones-in-atopic-dermatitis-study

Positive News For Skin Health: Aldeyra The...
12/19/2023 18:56:52

Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational R...

Market-Moving News for December 19th
12/19/2023 13:33:28

CGEN: 240% | Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Ph...

Aldeyra Therapeutics' Phase 2 Trial Of ADX...
12/19/2023 12:06:18

Aldeyra Therapeutics Schedules Conference ...
12/18/2023 21:03:28

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, Decem...

fda-rejects-aldeyra-therapeutics-dry-eye-disease-candidate-asks-for-additional-study

FDA Rejects Aldeyra Therapeutics' Dry Eye ...
11/28/2023 16:10:56

The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reprox...

Aldeyra Therapeutics Shares To Resume Trad...
11/27/2023 21:13:28

Aldeyra Therapeutics Receives Complete Res...
11/27/2023 21:08:58

why-extreme-networks-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Extreme Networks Shares Are Trading Lo...
11/01/2023 17:59:52

Gainers

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
11/01/2023 17:31:20

whats-going-on-with-aldeyra-therapeutics-stock

What's Going On With Aldeyra Therapeutics ...
11/01/2023 15:52:11

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares are trading higher Wednesday after the company announced that it entered into ...